Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Bortezomib and vorinostat may stop the growth of cancer cells by blocking some of
the enzymes needed for cell growth. Giving bortezomib together with vorinostat may kill more
cancer cells.
PURPOSE: This phase II trial is studying how well giving bortezomib together with vorinostat
works in treating patients with high-risk myelodysplastic syndrome or acute myelogenous
leukemia.
Phase:
Phase 2
Details
Lead Sponsor:
Masonic Cancer Center, University of Minnesota
Collaborators:
Merck Sharp & Dohme Corp. Millennium Pharmaceuticals, Inc.